| 词条 | Medical Research Council Technology |
| 释义 |
| name = LifeArc (formerly known as MRCTechnology) | logo = | caption = | trading_name = | native_name = | native_name_lang = | romanized = | former type = | type = Charity Commission for England and Wales | traded_as = | industry = Life science medical research charity | genre = | fate = Renamed LifeArc in 2017 | predecessor = | successor = | foundation = 2000 | founder = | defunct = | location_city = London | location_country = UK | locations = London, Stevenage, Edinburgh | area_served = | key_people = {{Unbulleted list|Dr John Stageman (Chairman) Melanie Lee (CEO)}} | products = | production = | services = IP management, drug discovery, diagnostics development, antibody engineering, charity portfolio review | revenue = {{Unbulleted list|£25.850 million (2017)|£128.967 million (2016)}} | operating_income = | net_income = | aum = | assets = | equity = | owner = | num_employees = 180 | parent = | divisions = | subsid = | homepage = {{URL|lifearc.org}} | footnotes = | intl = | bodystyle = }}LifeArc, formerly know as the Medical Research Council Technology (MRC Technology, MRCT) is a British life science medical research charity. It was established in 2000 to translate the work of UK Medical Research Council research scientists.[1] Today LifeArc provides intellectual property identification, protection and commercialisation, technology development, early stage drug discovery and antibody humanization services for the MRC, academia, biotechnology and pharmaceutical organisations and charities, aiming to move promising medical research forward into viable and accessible patient treatments. Profits from LifeArc's activities are reinvested into further research. HistoryLifeArc started as the Medical Research Council Liaison Office in 1984, and in 1986 the MRC Collaborative Centre, a laboratory-based technology transfer function, was founded. In 1993, the Liaison Office became MRC's Technology Transfer Group, responsible for office based patenting and licensing. The organisation was set up as a charity and a company limited by guarantee in 2000 to incorporate patenting, licensing and research functions.[2] On [https://www.lifearc.org/lifearc-set-transform-medical-research-landscape/ 15 June 2017] it officially became LifeArc. ActivitiesLifeArc has humanised a number of antibodies on behalf of other organisations. Four of these, Tysabri (Biogen Idec/Elan), Actemra (Hoffmann-La Roche/Chugai), Entyvio (Millenium Pharma/Takeda) and Keytruda (Merck/MSD), are now on the market.[3] In 2010, LifeArc signed a deal with the drug company AstraZeneca to share chemical compounds to help identify potential treatments for serious diseases.[4][5] LifeArc is a member of a Global Drug Discovery Alliance along with the Centre for Drug Research and Development, the Scripps Research Institute, Cancer Research Technology, the Lead Discovery Centre and the Centre for Drug Design and Discovery, dedicated to translating health research into new medicines and working together to improve the conversion of global early-stage research into much-needed new therapies.[6] Through its earnings from licensing agreements, LifeArc provides funding for academic research and early-stage medical research.[7] Dementia Consortium was launched in December 2013 - a unique £3m drug discovery collaboration between Alzheimer's Research UK, LifeArc and pharmaceutical companies Eisai and Lilly. In March 2019, LifeArc joined with Cancer Research UK and Ono Pharma to progress new immunotherapy drug targets for cancer.[8] Key achievements{{Unbulleted list| Over 400 commercial licences signed | Helped launch 12 drugs on the market | Helped form 18 start ups | Generated over £600 million in revenues for the MRC | Humanized two antibodies now on the market | Humanized six antibodies currently in clinical trials }} References1. ^Paul Feldman, Corinna Lotz, A world to win: a rough guide to a future without global capitalism, 2004, Lupus Books, {{ISBN|0952345412}}, 9780952345411 2. ^{{cite web |url=http://www.official-documents.gov.uk/document/other/0118404881/0118404881.pdf |title=A Review of UK Health Funding |publisher=The Stationery Office |author=Sir David Cooksey |date=2006-01-12 |page=20}} 3. ^{{cite web |url=http://www2.mrc-lmb.cam.ac.uk/achievements/therapeutic-antibodies |title=Therapeutic Antibodies and the LMB |publisher=MRC Laboratory of Molecular Biology |accessdate=2012-02-17 }}{{dead link|date=January 2018 |bot=InternetArchiveBot |fix-attempted=yes }} 4. ^Mark Wigglesworth, Terry Wood, eds, Management of Chemical and Biological Samples for Screening Applications, 2012, John Wiley & Sons, {{ISBN|3527645276}}, 9783527645275, [https://books.google.com/books?id=Hd6HRB4AWf8C&pg=PA390&dq google books] 5. ^{{cite web |url=http://www.astrazeneca.com/Media/Press-releases/Article/AstraZeneca-and-MRC-Technology-Form-Strategic-Alliance |title=AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research, Utilising Shared Compound Libraries |publisher=AstraZeneca |accessdate=2013-01-03}} 6. ^{{cite journal |journal=SciBX (Science-Business Exchange) |year=2013 |volume=6 |issue=4 |pages=78 |title=Translational Globetrotting |author=Edelson, Steve |doi=10.1038/scibx.2013.78 |url=http://www.nature.com/scibx/journal/v6/n4/full/scibx.2013.78.html }} 7. ^{{Cite web|url=https://www.stevenagecatalyst.com/news_and_events/news_archive1/news2017/lifearcset_to_transform_medical_research_landscape/|title=Stevenage BioScience Catalyst {{!}} LifeArc set to transform medical research landscape {{!}}|website=www.stevenagecatalyst.com|access-date=2019-03-30}} 8. ^{{Cite web|url=http://www.hospitalhealthcare.com/editors-pick/cancer-research-uk-lifearc-and-ono-pharma-form-cancer-therapy-alliance|title=Cancer Research UK, LifeArc and Ono Pharma form cancer therapy alliance|last=|first=|date=2019-03-28|website=Hospital Healthcare Europe|archive-url=|archive-date=|dead-url=|access-date=2019-03-30}} External links
4 : Technology transfer|Companies based in the London Borough of Camden|Medical research institutes in the United Kingdom|Charities based in London |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。